Monteleone, Giovanni http://orcid.org/0000-0003-1339-9076
Stolfi, Carmine
Marafini, Irene
Atreya, Raja
Neurath, Markus F.
Funding for this research was provided by:
Università degli Studi di Roma Tor Vergata
Article History
Accepted: 21 June 2022
First Online: 16 July 2022
Declarations
:
: Giovanni Monteleone served as a consultant for First Wave BioPharma and has filed a patent related to the treatment of inflammatory bowel diseases with Smad7 antisense oligonucleotides. Carmine Stolfi and Irene Marafini have no conflict of interests to declare. Raja Atreya received research grants from, or served as a member of advisory boards or speakers’ bureaus, for AbbVie, Amgen, Arena Pharmaceuticals, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion Healthcare, Dr Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, Fresenius Kabi, Galapagos, Gilead, GlaxoSmithKline plc, InDex Pharmaceuticals, Janssen-Cilag, Kiniksa Pharmaceuticals, MSD, Novartis, Pandion Therapeutics, Pfizer, Roche Pharma, Samsung Bioepis, Stelic Institute, Sterna Biologicals, Takeda Pharma, Tillotts Pharma AG, and Viatris. Markus F. Neurath served as a consultant for Pentax, Abbvie, Boehringer, PPM, Janssen, and Takeda.
: Not applicable.
: GM: Literature search, data collection and interpretation, and writing of the manuscript. CS, IM, RA and MFN: Critical revision of the manuscript.
: No specific funding has been received for this work. Open access funding provided by Università degli Studi di Roma Tor Vergata within the CRUI-CARE Agreement.
: Data describing the chemical properties of the mongersen batches are available in PubMed and can be accessed via the following doi link: ExternalRef removed. The post hoc analysis data shown in Fig. InternalRef removed were provided by Nogra Pharma Ltd. Data will be shared on request to the corresponding author with the permission of Nogra Pharma Ltd.
: Not applicable.